In the last trading session, 5.87 million Esperion Therapeutics Inc (NASDAQ:ESPR) shares changed hands as the company’s beta touched 1.03. With the company’s per share price at $1.73 changed hands at -$0.09 or -4.95% during last session, the market valuation stood at $340.87M. ESPR’s last price was a discount, traded about -127.75% off its 52-week high of $3.94. The share price had its 52-week low at $1.58, which suggests the last value was 8.67% up since then.
Analysts gave the Esperion Therapeutics Inc (ESPR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.78. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ESPR as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Esperion Therapeutics Inc’s EPS for the current quarter is expected to be -0.16.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Instantly ESPR was in red as seen at the end of in last trading. With action -7.49%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -21.36%, with the 5-day performance at -7.49% in the red. However, in the 30-day time frame, Esperion Therapeutics Inc (NASDAQ:ESPR) is -17.62% down.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 78.38% from its current market value. According to analyst projections, ESPR’s forecast low is 8 with 8 as the target high. To hit the forecast high, the stock’s price needs a -362.43% plunge from its current level, while the stock would need to soar -362.43% for it to hit the projected low.
Esperion Therapeutics Inc (ESPR) estimates and forecasts
Year-over-year growth is forecast to reach 179.14% up from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 61.58M. 5 analysts are of the opinion that Esperion Therapeutics Inc’s revenue for the current quarter will be 50.64M. The company’s revenue for the corresponding quarters a year ago was 32.25M and 137.74M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 90.96%. The estimates for the next quarter sales put growth at -63.23%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 23.09%. The 2025 estimates are for Esperion Therapeutics Inc earnings to increase by 84.40%.
ESPR Dividends
Esperion Therapeutics Inc is expected to release its next quarterly earnings report in March.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.2617% or 13.98 million shares worth $31.04 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund . With 6.68 shares estimated at $11.55 million under it, the former controlled 3.39% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.14% of the shares, roughly 6.18 shares worth around $10.69 million.
